Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 924131, 8 pages
http://dx.doi.org/10.1155/2015/924131
Research Article

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia

1Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
2Department of Cardiology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Received 24 August 2015; Accepted 30 September 2015

Academic Editor: Nguan Soon Tan

Copyright © 2015 Xiaomeng Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [9 citations]

The following is the list of published articles that have cited the current article.

  • Jun Zhang, Xin Liu, Xian-Bin Xie, Xian-Chao Cheng, and Run-Ling Wang, “Multitargeted bioactive ligands for PPARs discovered in the last decade,” Chemical Biology & Drug Design, 2016. View at Publisher · View at Google Scholar
  • Yan Qiu, and Meng-Ge Song, “Study on the serum irisin level in patients with polycystic ovary syndrome,” Journal of Shanghai Jiaotong University (Medical Science), vol. 36, no. 6, pp. 890–895, 2016. View at Publisher · View at Google Scholar
  • Xiaomeng Feng, Xia Gao, Heng Zhang, Yumei Jia, Yuan Xu, and Guang Wang, “PPAR-α agonist fenofibrate decreased rantes levels in type 2 diabetes patients with hypertriglyceridemia,” Medical Science Monitor, vol. 22, pp. 743–751, 2016. View at Publisher · View at Google Scholar
  • Chenshu Xu, Min Huang, and Huichang Bi, “PXR- and CAR-mediated herbal effect on human diseases,” Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2016. View at Publisher · View at Google Scholar
  • M. Croyal, Z. Kaabia, L. León, S. Ramin-Mangata, T. Baty, F. Fall, S. Billon-Crossouard, A. Aguesse, T. Hollstein, D.R. Sullivan, E. Nobecourt, G. Lambert, and M. Krempf, “Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD?,” Diabetes & Metabolism, 2017. View at Publisher · View at Google Scholar
  • Xiaomeng Feng, Xia Gao, Yumei Jia, and Yuan Xu, “PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study,” Diabetes Therapy, 2017. View at Publisher · View at Google Scholar
  • Ayse Sahin-Efe, Jagriti Upadhyay, Byung-Joon Ko, Fadime Dincer, Kyung Hee Park, Alexandra Migdal, Pantel Vokonas, and Christos Mantzoros, “Irisin and Leptin Concentrations in relation to Obesity, and Developing Type 2 Diabetes: a cross sectional and a prospective case-control study nested in the Normative Aging Study,” Metabolism, 2017. View at Publisher · View at Google Scholar
  • Jun Zhang, Qing-Qing Hao, Xin Liu, Zhi Jing, Wen-Qing Jia, Shu-Qing Wang, Wei-Ren Xu, Xian-Chao Cheng, and Run-Ling Wang, “Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARγ,” Oncotarget, vol. 8, no. 15, pp. 25612–25627, 2017. View at Publisher · View at Google Scholar
  • Vincenzo Sorrentino, Keir J. Menzies, and Johan Auwerx, “Repairing Mitochondrial Dysfunction in Disease,” Annual Review of Pharmacology and Toxicology, vol. 58, no. 1, pp. 353–389, 2018. View at Publisher · View at Google Scholar